Background Interferon beta reduces activity in multiple sclerosis as measured clinically and
by magnetic resonance imaging (MRI). We assessed the effect of interferon beta-1a on the …

Objective This study was undertaken to assess the impact of immunosuppressive and
immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID‐19) in people …

Background The 2001 and 2005 McDonald criteria allow MRI evidence for dissemination in
space (DIS) and dissemination in time (DIT) to be used to diagnose multiple sclerosis in …

The secondary progressive phase of multiple sclerosis (MS), which is characterised by a
steady accrual of fixed disability after an initial relapsing remitting course, is not clearly …

In patients who present with clinically isolated syndromes suggestive of multiple sclerosis,
interferon beta-1a is effective in delaying evolution to clinically definite disease and in …

Although the diagnosis of multiple sclerosis relies on the demonstration of disease dissemination
in space and time, the exclusion of other neurological disorders is also essential. The …

Background Mitoxantrone (MX) has been shown to be moderately effective in reducing the
clinical outcome measures of disease activity in multiple sclerosis (MS) patients.

Previous studies assessing the magnetic resonance imaging (MRI) correlates of cognitive
dysfunction in multiple sclerosis (MS) achieved conflicting results. Diffusion tensor (DT)-MRI …

It has been suggested that sleep disturbances in multiple sclerosis (MS) may be related to
periodic leg movements (PLM) during sleep, but to date polysomnographic studies were …

BACKGROUND AND PURPOSE: Progressive brain atrophy is a well-known feature of
multiple sclerosis (MS). We characterized the spatial evolution of atrophy in different MS …